BCLI : Summary for Brainstorm Cell Therapeutics In - Yahoo Finance

U.S. Markets open in 8 hrs 43 mins

Brainstorm Cell Therapeutics Inc. (BCLI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.51+0.57 (+14.47%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close3.94
Bid4.51 x 200
Ask4.75 x 400
Day's Range3.81 - 4.64
52 Week Range2.06 - 4.64
Avg. Volume234,336
Market Cap84.28M
PE Ratio (TTM)-14.64
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Investopedia2 days ago

    BrainStorm Seeks ALS Drug Approval In Canada

    BrainStorm is seeking early approval in Canada for its ALS drug.

  • PR Newswire2 days ago

    BrainStorm Seeking Approval To Distribute NurOwn® in Canada

    TORONTO, HACKENSACK, N.J. and PETACH TIKVAH, Israel, Feb. 21, 2017 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, has signed an agreement with CCRM, a Toronto-based leader in developing and commercializing regenerative medicine technologies, and cell and gene therapies, to support the market authorization request for NurOwn®.   At this time, CCRM is helping Brainstorm explore the opportunity to access Health Canada's early access pathway for treatment of patients with Amyotrophic Lateral Sclerosis (ALS).  If NurOwn® qualifies for Health Canada's "Notice of Compliance with Conditions" pathway, it could be authorized in Canada for distribution in early 2018.

  • CNW Group2 days ago

    BrainStorm Seeking Approval To Distribute NurOwn® in Canada

    BrainStorm Seeking Approval To Distribute NurOwn® in Canada